A6X Stock Chart & Stats
€0.21
<€0.01(1.32%)
At close: 4:00 PM EST
€0.21
<€0.01(1.32%)
Day’s Range― - ―
52-Week Range€0.07 - €0.32
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€22.07M
Enterprise Value€95.80
Total Cash (Recent Filing)€4.00M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.07
Next Earnings
Aug 27, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding67,729,120
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)2.33
Price to Sales (P/S)6.68
P/FCF Ratio-7.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€3.53M
Bulls Say, Bears Say
Bulls Say
Proprietary Active IngredientOwning a proprietary compound (phenylcapsaicin) provides a durable competitive asset: it can be licensed, formulated into differentiated products, and applied across feed and other segments. This platform characteristic supports long-term product moat and multiple commercialization paths.
Revenue Growth And Margin RecoveryRising revenue and a recovery to ~16% gross margin show improving unit economics and early scale effects. Durable margin improvement versus a prior sharply negative figure suggests operational fixes or better mix that can underpin eventual profitability if sustained.
Low Financial LeverageA zero-debt balance sheet with significant equity reduces refinancing risk and gives the company flexibility to fund R&D or commercial rollouts from capital or via equity raises. This structural strength lengthens runway and supports strategic options over months.
Bears Say
Persistent Operating LossesVery wide negative EBIT and net margins indicate the core business has not reached sustainable profitability. Prolonged losses erode equity, limit reinvestment capacity, and make long-term viability contingent on meaningful margin improvement or external funding.
Negative Cash Flow / Cash BurnConsistent negative operating and free cash flow means the business consumes cash to run and grow. Even with no acceleration in burn, reliance on external funding or equity reduces financial resilience and constrains the pace of commercial expansion sustainably.
Unclear Commercial Partnerships & Revenue MixLack of disclosed long-term contracts or named partners implies revenue may be concentrated and dependent on spot sales to feed producers. Unquantified licensing/collaboration potential increases execution risk when scaling, slowing predictable, durable revenue growth.
aXichem AB Class A News
A6X FAQ
What was aXichem AB Class A’s price range in the past 12 months?
aXichem AB Class A lowest stock price was €0.07 and its highest was €0.32 in the past 12 months.
What is aXichem AB Class A’s market cap?
aXichem AB Class A’s market cap is €22.07M.
When is aXichem AB Class A’s upcoming earnings report date?
aXichem AB Class A’s upcoming earnings report date is Aug 27, 2026 which is in 24 days.
How were aXichem AB Class A’s earnings last quarter?
aXichem AB Class A released its earnings results on May 21, 2026. The company reported -€0.012 earnings per share for the quarter, the consensus estimate of -€0.012 by €0.
Is aXichem AB Class A overvalued?
According to Wall Street analysts aXichem AB Class A’s price is currently Overvalued.
Does aXichem AB Class A pay dividends?
aXichem AB Class A does not currently pay dividends.
What is aXichem AB Class A’s EPS estimate?
aXichem AB Class A’s EPS estimate is -0.01.
How many shares outstanding does aXichem AB Class A have?
aXichem AB Class A has 67,729,120 shares outstanding.
What happened to aXichem AB Class A’s price movement after its last earnings report?
aXichem AB Class A reported an EPS of -€0.012 in its last earnings report, expectations of -€0.012. Following the earnings report the stock price went up 4.301%.
Which hedge fund is a major shareholder of aXichem AB Class A?
Currently, no hedge funds are holding shares in DE:A6X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
aXichem AB Class A
aXichem AB is a biotechnology firm, established in 2007 and headquartered in Malmö, Sweden, that specializes in creating natural analogue compounds. The company offers aXivite, a capsaicin analogue solution designed for various dietary health applications. Another key product, aXiphen-bio, functions as a biological repellent, providing antifouling protection for marine vessels and installations, and managing pests in agriculture, forestry, and for safeguarding cable infrastructure both within buildings and underground. Additionally, aXiphen-feed is developed to boost the health of poultry, including chickens and hens, as well as swine, such as pigs and piglets.
Technical Analysis
Nexam Chemical Holding AB
―
―
Svenska Aerogel Holding AB
―
OrganoClick AB
―
XP Chemistries AB
―